Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Tre...
December 13 2019 - 8:30AM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development, and commercialization of
novel therapies for the treatment of cancer, today announced
results from a pivotal Phase III clinical trial showed oral
paclitaxel and encequidar had superior response and survival with
much lower incidence and severity of neuropathy compared to IV
paclitaxel in the treatment of metastatic breast cancer. For
additional details on the study results, please refer to the
abstract GS6-01, which can be found online here.
Dr. Rudolf Kwan, Chief Medical Officer of Athenex, commented,
“Oral paclitaxel and encequidar is the first oral taxane to
demonstrate in a Phase III study statistically significant
improvement in response rate and median overall survival compared
to IV paclitaxel, in the treatment of metastatic breast cancer
while associated with a much lower incidence and severity of
neuropathy. We believe these data suggest the potential for
oral paclitaxel and encequidar to provide an important advance in
the management of patients with metastatic breast cancer.”
These results will be presented in an oral presentation today at
the 2019 San Antonio Breast Cancer Symposium (SABCS) at 3:15 p.m.
CT in General Session 6 in Hall 3 of the Henry B. Gonzalez
Convention Center in San Antonio, Texas, and were selected for the
official SABCS press program at 7:30 a.m. CT.
The Orascovery platform was initially developed by Hanmi
Pharmaceuticals and licensed exclusively to Athenex for all major
worldwide territories except Korea, which is retained by Hanmi.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development, and commercialization of next-generation
drugs for the treatment of cancer. Athenex is organized around
three platforms, including an Oncology Innovation Platform, a
Commercial Platform, and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on nonabsorbed
P-glycoprotein inhibition, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices in Buffalo and Clarence, New York;
Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong;
Taipei, Taiwan; multiple locations in Chongqing, China; Manchester,
UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more
information, please visit www.athenex.com.
Forward-Looking Statements
Except for historical information, all of the statements,
expectations, and assumptions contained in this press release are
forward-looking statements. These forward-looking statements are
typically identified by terms such as “anticipate,” “believe,”
“continue,” “could,” “estimate,” “evaluate,” “expect,” “foresee,”
“guidance,” “intend,” “investigate,” “likely,” “may,” “plan,”
“potential,” “predict,” “preliminary,” “prepare,” “potential,”
“probable,” “project,” “promising,” “seek,” “should,” “will,”
“would,” and similar expressions. Actual results might differ
materially from those explicit or implicit in the forward-looking
statements. Important factors that could cause actual results to
differ materially include: the development stage of our primary
clinical candidates and related risks involved in drug development,
clinical trials, regulation, manufacturing and commercialization;
our reliance on third parties for success in certain areas of
Athenex’s business; our history of operating losses and need to
raise additional capital to continue as a going concern; our
ability to integrate CIDAL’s assets into our existing operations;
competition; intellectual property risks; risks relating to doing
business in China; the uncertainty of when, if at all, we will
be able to resume producing API in our Chongqing plant;
and the other risk factors set forth from time to time in
our SEC filings, copies of which are available for free
in the Investor Relations section of our website
at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or
upon request from our Investor Relations Department. All
information provided in this release is as of the date hereof and
we assume no obligation and do not intend to update these
forward-looking statements, except as required by law.
CONTACTSAthenex, Inc.:Jacqueline LiCorporate
Development and Investor RelationsEmail:
JacquelineLi@athenex.com
Investor Relations:Tim McCarthyManaging Director, LifeSci
Advisors, LLCDirect: 212-915-2564
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Sep 2023 to Sep 2024